ValuEngine upgraded shares of Evoke Pharma, Inc. (NASDAQ:EVOK) from a sell rating to a hold rating in a research report released on Thursday, July 20th.
Separately, FBR & Co reaffirmed a buy rating and set a $9.00 target price on shares of Evoke Pharma in a report on Thursday, May 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Evoke Pharma currently has an average rating of Hold and a consensus price target of $7.25.
Shares of Evoke Pharma (NASDAQ:EVOK) opened at 2.27 on Thursday. The firm’s 50-day moving average price is $2.47 and its 200-day moving average price is $2.72. Evoke Pharma has a 52-week low of $1.35 and a 52-week high of $4.55. The firm’s market capitalization is $34.93 million.
Evoke Pharma (NASDAQ:EVOK) last posted its earnings results on Monday, May 15th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. During the same period in the prior year, the business earned ($0.45) EPS. On average, equities analysts predict that Evoke Pharma will post ($0.84) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Evoke Pharma, Inc. (EVOK) Upgraded to “Hold” at ValuEngine” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/10/evoke-pharma-inc-evok-raised-to-hold-at-valuengine-updated-updated.html.
A hedge fund recently raised its stake in Evoke Pharma stock. State Treasurer State of Michigan raised its position in Evoke Pharma, Inc. (NASDAQ:EVOK) by 62.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 291,966 shares of the specialty pharmaceutical company’s stock after buying an additional 111,966 shares during the period. State Treasurer State of Michigan owned approximately 2.37% of Evoke Pharma worth $905,000 as of its most recent filing with the SEC. 12.40% of the stock is currently owned by institutional investors and hedge funds.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
